Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis

Eda AÇIKGÖZ, (Department of Histology and Embryology, Van Yuzuncu Yil University, Faculty of Medicine, Van, Türkiye)
Mustafa Cakir, (Department of Medical Biology, Van Yuzuncu Yil University, Faculty of Medicine, Van, Türkiye)
Mustafa Guven, (Department of Medicine, Van Yuzuncu Yil University, Faculty of Medicine, Van, Türkiye)
Gülperi ÖKTEM (Department of Stem Cell, Institute of Health Science, Ege University, Izmir, Türkiye)
Eurasian Journal of Medicine and Oncology
1 0
Yıl: 2021 Cilt: 5 Sayı: 4 Sayfa Aralığı: 299 - 304 Metin Dili: İngilizce DOI: 10.14744/ejmo.2021.11927 İndeks Tarihi: 17-05-2022

Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis

Öz:
Objectives: Cancer stem cells (CSCs), a small subpopulation of tumors, are responsible for chemo-radioresistance, metastasis, and cancer recurrence. The main aim of the present study is to investigate the potential effects of metformin on prostate CSCs (PCSCs). Methods: Flow cytometry was used to isolate cells with co-expression of CD133 and CD44. Sorted PCSCs were treated with different concentrations of metformin to determine the effects of metformin on cell viability using MTT assay. The association of cells exposure to metformin with apoptotic cell death and caspase activity, as well as cell cycle, were performed using the Muse Cell Analyzer. Results: In our study, for the first time we demonstrated the anti-cancer effects of metformin on PCSCs. Our results revealed that treatment with metformin reduced cell viability in CD133high/CD44high cells in a dose- and time-dependent manner. Metformin significantly induced early apoptosis and triggered the activity of several caspases associated with the apoptotic process. Metformin significantly altered the cell cycle distribution in CD133high/CD44high cells, leading to G0/G1 phase arrest. Conclusion: The results of the study revealed that metformin triggers cell death and apoptosis and modulates cell cycle distribution in CD133high/CD44high PCSCS. The present study raises the possibility that metformin is a potential anti-cancer agent for targeting PCSCs.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Kappen S, de Bock GH, Sirri E, Vohmann C, Kieschke J, Winter A. Differences in prostate cancer incidence and mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential impact of prostate-specific antigen testing. Front Oncol 2011;11:681006. Available from: https://www. frontiersin.org/article/10.3389/fonc.2021.681006. Accessed Nov 29, 2021.
  • 2. Pirtskhalaishvili G, Hrebinko RL, Nelson JB. The Treatment of Prostate Cancer. Cancer Pract 200;9:295–306.
  • 3. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012;22:457–72.
  • 4. Thankamony AP, Saxena K, Murali R, Jolly MK, Nair R. Cancer stem cell plasticity – a deadly deal. Front Mol Biosci 2020;7:79. 5. Batlle E, Clevers H. Cancer stem cells revisited. Nat Med 2017;23:1124–34.
  • 6. Zhou H-M, Zhang J-G, Zhang X, Li Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct Target Ther 2021;6:62.
  • 7. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946–51.
  • 8. Mei W, Lin X, Kapoor A, Gu Y, Zhao K, Tang D. The contributions of prostate cancer stem cells in prostate cancer initiation and metastasis. Cancers (Basel) 2019;11:434.
  • 9. Acikgoz E, Guven U, Duzagac F, Uslu R, Kara M, Soner BC, et al. Enhanced G2/M arrest, caspase related apoptosis and reduced E-cadherin dependent intercellular adhesion by trabectedin in prostate cancer stem cells. PLoS One 2015;10:e0141090.
  • 10. Soner BC, Aktug H, Acikgoz E, Duzagac F, Guven U, Ayla S, et al. Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+prostate cancer stem cells by flavopiridol. Int J Mol Med 2014;34:1249–56.
  • 11. Acikgoz E, Mukhtarova G, Alpay A, Avci CB, Bagca BG, Oktem G. Sonic hedgehog signaling is associated with resistance to zoledronic acid in CD133high/CD44high prostate cancer stem cells. Mol Biol Rep 2021;48:3567–78.
  • 12. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304–5.
  • 13. Whitburn J, Edwards CM, Sooriakumaran P. Metformin and Prostate Cancer: A new role for an old drug. Curr Urol Rep 2017;18:46.
  • 14. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507–11.
  • 15. Brown JR, Chan DK, Shank JJ, Griffith KA, Fan H, Szulawski R, et al. Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight 2020;5:e133247.
  • 16. Zhang Y, Guan M, Zheng Z, Zhang Q, Gao F, Xue Y. Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS One 2013;8:e81264.
  • 17. Würth R, Pattarozzi A, Gatti M, Bajetto A, Corsaro A, Parodi A, et al. Metformin selectively affects human glioblastoma tumor- initiating cell viability: A role for metformin-induced inhibition of Akt. Cell Cycle 2013;12:145–56.
  • 18. Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, et al. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol 2013;6:649–59.
  • 19. Mayer MJ, Klotz LH, Venkateswaran V. Metformin and prostate cancer stem cells: a novel therapeutic target. Prostate Cancer Prostatic Dis 2015;18:303–9.
  • 20. Aghajani M, Mokhtarzadeh A, Aghebati-Maleki L, Mansoori B, Mohammadi A, Safaei S, et al. CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel. Mol Biol Rep 2020;47:3691–703.
  • 21. Wróbel T, Luty M, Catapano J, Karnas E, Szczygieł M, Piwowarczyk K, et al. CD44+ cells determine fenofibrate-induced microevolution of drug-resistance in prostate cancer cell populations. Stem Cells 2020;38:1544–56.
  • 22. Chen X, Li C, He T, Mao J, Li C, Lyu J, et al. Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression. Cancer Biol Ther 2016;17:507–14.
  • 23. Yang Y, Wu X-H. Study on the influence of metformin on castration- resistant prostate cancer PC-3 cell line biological behavior by its inhibition on PLCε gene-mediated Notch1/Hes and androgen receptor signaling pathway. Eur Rev Med Pharmacol Sci 2017;21:1918–23.
  • 24. Wang Y, Liu G, Tong D, Parmar H, Hasenmayer D, Yuan W, et al. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor. Prostate 2015;75:1187–96.
  • 25. Queiroz EAIF, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One 2014;9:e98207.
  • 26. Sahra I Ben, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576–86.
  • 27. Leist M, Jäättelä M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2:589– 98.
  • 28. Kitanaka C, Kuchino Y. Caspase-independent programmed cell death with necrotic morphology. Cell Death Differ 1999;6:508–15.
  • 29. Jang JH, Sung EG, Song IH, Lee TJ, Kim JY. Metformin induces caspase-dependent and caspase-independent apoptosis in human bladder cancer T24 cells. Anticancer Drugs 2020;31:655–62.
  • 30. Xie Y, Wang L, Khan MA, Hamburger AW, Guang W, Passaniti A, et al. Metformin and Androgen Receptor-Axis-Targeted (ARAT) agents induce two PARP-1-dependent cell death pathways in androgen-sensitive human prostate cancer cells. Cancers (Basel) 2021;13:633.
  • 31. Lu C-C, Chiang J-H, Tsai F-J, Hsu Y-M, Juan Y-N, Yang J-S, et al. Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling. Int J Oncol 2019;54:1271– 81.
APA Acikgoz E, Çakır M, Güven M, Öktem G (2021). Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis. , 299 - 304. 10.14744/ejmo.2021.11927
Chicago Acikgoz Eda,Çakır Mustafa,Güven Mustafa,Öktem Gülperi Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis. (2021): 299 - 304. 10.14744/ejmo.2021.11927
MLA Acikgoz Eda,Çakır Mustafa,Güven Mustafa,Öktem Gülperi Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis. , 2021, ss.299 - 304. 10.14744/ejmo.2021.11927
AMA Acikgoz E,Çakır M,Güven M,Öktem G Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis. . 2021; 299 - 304. 10.14744/ejmo.2021.11927
Vancouver Acikgoz E,Çakır M,Güven M,Öktem G Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis. . 2021; 299 - 304. 10.14744/ejmo.2021.11927
IEEE Acikgoz E,Çakır M,Güven M,Öktem G "Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis." , ss.299 - 304, 2021. 10.14744/ejmo.2021.11927
ISNAD Acikgoz, Eda vd. "Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis". (2021), 299-304. https://doi.org/10.14744/ejmo.2021.11927
APA Acikgoz E, Çakır M, Güven M, Öktem G (2021). Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis. Eurasian Journal of Medicine and Oncology, 5(4), 299 - 304. 10.14744/ejmo.2021.11927
Chicago Acikgoz Eda,Çakır Mustafa,Güven Mustafa,Öktem Gülperi Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis. Eurasian Journal of Medicine and Oncology 5, no.4 (2021): 299 - 304. 10.14744/ejmo.2021.11927
MLA Acikgoz Eda,Çakır Mustafa,Güven Mustafa,Öktem Gülperi Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis. Eurasian Journal of Medicine and Oncology, vol.5, no.4, 2021, ss.299 - 304. 10.14744/ejmo.2021.11927
AMA Acikgoz E,Çakır M,Güven M,Öktem G Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis. Eurasian Journal of Medicine and Oncology. 2021; 5(4): 299 - 304. 10.14744/ejmo.2021.11927
Vancouver Acikgoz E,Çakır M,Güven M,Öktem G Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis. Eurasian Journal of Medicine and Oncology. 2021; 5(4): 299 - 304. 10.14744/ejmo.2021.11927
IEEE Acikgoz E,Çakır M,Güven M,Öktem G "Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis." Eurasian Journal of Medicine and Oncology, 5, ss.299 - 304, 2021. 10.14744/ejmo.2021.11927
ISNAD Acikgoz, Eda vd. "Metformin Eliminates CD133high/CD44high Prostate Cancer Stem Cells Via Cell Cycle Arrest and Apoptosis". Eurasian Journal of Medicine and Oncology 5/4 (2021), 299-304. https://doi.org/10.14744/ejmo.2021.11927
Sayfa Oluşturulma Tarihi
23-04-2024 22:14

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları